Evidence map›Paper›PMID 18816788›Full record

ArticleJournal of neuroscience research2009

Differential alteration of hippocampal excitatory synaptic transmission by cannabinoid ligands.

Michal Bajo, Marisa Roberto, Paul Schweitzer

Abstract read
In one paragraph

Article in Journal of neuroscience research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Genetic control of astrocyte function in neural circuits.Frontiers in cellular neuroscience · 2015
    Review
  5. Article
  6. Article
  7. Article
  8. The endocannabinoid system tonically regulates inhibitory transmission and depresses the effect of ethanol in central amygdala.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michal BajoMolecular and Integrative Neurosciences Department, The Scripps Research Institute, La Jolla, California 92037, USA.
Marisa Roberto
Paul Schweitzer
Scripps Research Institute · US

Funding

Viral Vector CoreP60AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI Remi Martin-Fardon · 2003 to 2026
$46.3M
SYSTEMIC NEUROPHARMACOLOGYP50AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE · PI RIVIER, CATHERINE L · 1985 to 2002
$5.1M
Cannabinoids and Central Neuronal ActivityR01DA013658 · NIDA · SCRIPPS RESEARCH INSTITUTE · PI SCHWEITZER, PAUL P · 2001 to 2005
$1.5M
NIAAA NIH HHS AA06420NIAAA NIH HHS P50 AA006420NIAAA NIH HHS P60 AA006420NIDA NIH HHS DA13658NIDA NIH HHS R01 DA013658
6 · The paper itself

Abstract

Cannabinoid compounds affect synaptic activity and plasticity in numerous brain areas by activating CB1 receptors (CB1). In hippocampus, varying results have been obtained on the extent and site of cannabinoid actions on excitatory transmission, ranging from no effect to complete obliteration of synaptic responses. Here we used the rat hippocampal slice preparation to study and compare the effect of various synthetic and endogenous CB1 ligands on excitatory synaptic transmission. The full CB1 agonist WIN55212-2 (WIN2) greatly decreased excitatory synaptic transmission by 62%. The effect of WIN-2 was concentration dependent (EC50 of 200 nM) and completely prevented by CB1 antagonists. The nondegradable partial CB1 agonist R1-methanandamide (mAEA) decreased transmission by 25% and the endocannabinoids 2-arachidonylglycerol (2-AG) and anandamide (AEA) had no significant effect. The action of AEA was improved by inhibiting its degradation but not its transport. The effect of 2-AG was enhanced upon inhibition of COX-2 but remained unchanged with blockade of monoacylglycerol lipase (MAGL). The observed effects were prevented by CB1 antagonists regardless of the ligand used, and paired-pulse paradigms pointed to presynaptic mechanisms of cannabinoid action. Our results show that cannabinoid effects on neuronal activity differ widely according to the CB1 ligand used. We observed large differences between full (synthetic) and partial (endogenous) CB1 agonists in altering synaptic transmission, notably because of the involvement of active degradation mechanisms.

Indexed as

AnimalsArachidonic AcidsBenzoxazinesCyclooxygenase 2Cyclooxygenase 2 InhibitorsElectric StimulationEndocannabinoidsExcitatory Postsynaptic PotentialsGlyceridesHippocampusIn Vitro TechniquesLigandsMaleMonoacylglycerol LipasesMorpholinesNaphthalenes(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneanandamideArachidonic AcidsBenzoxazinesCyclooxygenase 2Cyclooxygenase 2 InhibitorsEndocannabinoidsGlyceridesglyceryl 2-arachidonateLigandsmethanandamideMonoacylglycerol LipasesMorpholinesNaphthalenesPolyunsaturated AlkamidesPtgs2 protein, ratReceptor, Cannabinoid, CB1

Identifiers

PMID18816788
PMCPMC3816768
OpenAlexW2126313274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.